SENS-401: Clinical Trials

4 trials of SENS-401, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 3 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 11Completed 1
Phase 31Completed 1

Follow SENS-401: new trials by email Literature Review of SENS-401 trials Research Report on SENS-401

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
SENS-401 (R-Azasetron Besylate) - Hearing Loss Ototoxic
Phase 2CompletedSensorion482022-12-302026-07-02
Evaluation of the Presence of SENS-401 in the Perilymph
SENS-401 (R-Azasetron Besylate) - Hearing Loss
Phase 2CompletedSensorion282022-08-102025-04-23
Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
SENS-401, Placebo Oral Tablet - Severe Sudden Sensorineural Hearing Loss
Phase 2 / Phase 3CompletedSensorion1152019-02-152023-03-01
A Study of SENS 401 in Healthy Subjects
SENS-401, Placebo - Inner Ear Disease
Phase 1CompletedSimbec Research362016-10-212019-04-08

Conditions studied

Hearing Loss (1)  ·  Hearing Loss, Sudden (1)  ·  Labyrinth Diseases (1)

Sponsors

Sensorion (3)  ·  Simbec Research (1)

Countries

France (3)  ·  United Kingdom (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  Germany (1)  ·  Israel (1)  ·  Serbia (1)  ·  Slovakia (1)  ·  Turkey (Türkiye) (1)

Top investigators

Robert Adams, MBBS (1)  ·  Stephen O'Leary, MD (1)